- Home
- BMBL vs CDMO Comparison
BMBL vs CDMO Comparison
Compare BMBL & CDMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMBL
- CDMO
- Stock Information
- Founded
- BMBL 2014
- CDMO 1981
- Country
- BMBL United States
- CDMO United States
- Employees
- BMBL N/A
- CDMO N/A
- Industry
- BMBL Computer Software: Prepackaged Software
- CDMO Biotechnology: Pharmaceutical Preparations
- Sector
- BMBL Technology
- CDMO Health Care
- Exchange
- BMBL Nasdaq
- CDMO Nasdaq
- Market Cap
- BMBL 838.4M
- CDMO 784.1M
- IPO Year
- BMBL 2021
- CDMO N/A
- Fundamental
- Price
- BMBL $7.75
- CDMO $12.30
- Analyst Decision
- BMBL Hold
- CDMO Hold
- Analyst Count
- BMBL 16
- CDMO 3
- Target Price
- BMBL $8.38
- CDMO $12.25
- AVG Volume (30 Days)
- BMBL 2.2M
- CDMO 1.2M
- Earning Date
- BMBL 11-06-2024
- CDMO 12-10-2024
- Dividend Yield
- BMBL N/A
- CDMO N/A
- EPS Growth
- BMBL N/A
- CDMO N/A
- EPS
- BMBL N/A
- CDMO N/A
- Revenue
- BMBL $1,083,632,000.00
- CDMO $150,445,000.00
- Revenue This Year
- BMBL $3.82
- CDMO $19.05
- Revenue Next Year
- BMBL N/A
- CDMO $20.88
- P/E Ratio
- BMBL N/A
- CDMO N/A
- Revenue Growth
- BMBL 6.26
- CDMO 6.75
- 52 Week Low
- BMBL $4.80
- CDMO $5.65
- 52 Week High
- BMBL $15.33
- CDMO $12.48
- Technical
- Relative Strength Index (RSI)
- BMBL 43.02
- CDMO 62.08
- Support Level
- BMBL $7.91
- CDMO $12.28
- Resistance Level
- BMBL $8.58
- CDMO $12.39
- Average True Range (ATR)
- BMBL 0.47
- CDMO 0.09
- MACD
- BMBL -0.14
- CDMO -0.06
- Stochastic Oscillator
- BMBL 21.47
- CDMO 67.86
About BMBL Bumble Inc.
Bumble Inc is engaged in offering online dating services. The company operates two apps, Bumble and Badoo, where users come every month to discover new people and connect.
About CDMO Avid Bioservices Inc.
Avid Bioservices Inc is a clinical-stage biopharmaceutical company focused on the development and Current Good Manufacturing Practices (CGMP) of biopharmaceutical products derived from mammalian cell culture. Its business is organized into one reportable operating segment which is contract manufacturing and development services segment. Its services include clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. The company also provides a variety of process development services including cell line development, upstream and downstream development and optimization, analytical method development, testing and characterization.